Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHPS | P49366 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 17/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404852 | 0.89 | TRPV1 (0.43) | DHPSTRPV1NPC1LMNACYP1A2 | |
| SCHEMBL6409205 | 0.83 | NR3C1 (0.48) | DHPSTRPV1 | |
| SCHEMBL6410296 | 0.73 | NR3C1 (0.59) | TRPV1NPC1LMNACYP1A2CYP3A4 | |
| SCHEMBL5800297 | 0.72 | NR3C1 (0.48) | DHPSTRPV1 | |
| SCHEMBL5777188 | 0.72 | NR3C1 (0.49) | TRPV1 | |
| SCHEMBL3693681 | 0.71 | MAPT (0.55) | LMNACYP1A2CYP3A4HPGDCYP2C19 | |
| SCHEMBL27497175 | 0.70 | PGR (0.74) | — | |
| SCHEMBL5796840 | 0.70 | NR3C1 (0.55) | DHPSTRPV1 | |
| SCHEMBL3649826 | 0.69 | NR3C1 (0.58) | CYP1A2CYP3A4HPGDCYP2C19 | |
| SCHEMBL5802391 | 0.67 | NR3C1 (0.69) | TRPV1NPC1LMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090559-A1 | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents | IL1B, NFKBIA, BBOX1 | DHPS 198/4885TRPV1 743/4885NPC1 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.